- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
EP: 5.Key Highlights from EV-302 Study at ESMO 2023
EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023
EP: 7.Future Opportunities in Genitourinary Cancers
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the TAR-200 “pretzel” intravesical delivery device studies for BCG-unresponsive non–muscle invasive bladder cancer. The TAR-200 silicone device releases gemcitabine over 3 weeks when placed in the bladder via catheter. Early phase 1 studies showed good tolerability.
The SunRISe-1 study tested TAR-200 with or without the PD-1 inhibitor cetrelimab versus cetrelimab alone in BCG-unresponsive patients. In the TAR-200 alone cohort (n = 30), complete response rates were 77% to 80%, much higher than expected. Cetrelimab alone had a 38% complete response rate, like pembrolizumab. This suggests the device itself is contributing significant efficacy.
Daneshmand notes the TAR-200 device is a promising novel therapeutic option that is well tolerated. Future studies will evaluate combinations and utility across disease settings. The SunRISe 2-4 studies are testing TAR-200 in muscle-invasive bladder cancer, BCG-naive patients, and neoadjuvantly, respectively. Early data showed TAR-200 activity even in muscle-invasive disease. These large ongoing trials will help determine optimal integration of the TAR-200 device for bladder cancer.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
